The COAPT Trial

The COAPT Trial is a trial in the U.S. and Canada that will study an investigational device in patients who have functional mitral regurgitation and are considered extremely high-risk for mitral valve surgery.

Patients will be randomly assigned to a Device Group or Control Group. Both groups will receive the current recommended treatment, also known as the standard of care. For patients with mitral regurgitation who are considered extremely high-risk for mitral valve surgery, the standard of care may include one or more of these therapies:

  • Medications
  • Implantation of a pacemaker, a device that delivers electrical impulses to help the heart beat normally
  • Treatments for coronary artery disease

The COAPT Trial will study up to 430 patients at as many as 75 medical centers in the U.S.

Learn more about the device and control groups »